Back

Perceived effectiveness of PCSK9i-SiRNA therapy and adherence to background statin therapy: real-world analysis of the DAMAGE registry

28 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Novel lipid‑lowering therapies for residual risk Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Associate Professor Federico Guerra

Marche Polytechnic University of Ancona, Ancona (Italy)

6 More presentations in this session

Presentation thumbnail
Efficacy of enlicitide, an oral PCSK9 inhibitor, across baseline Lp(a) strata in an analysis of two phase 3 trials
Doctor P. Corral (Mar del Plata, AR)
Abstract Slides Video
Presentation thumbnail
Adherence and legacy effects of high dose eicosapentaenoic acid in hypertriglyceridemia and high CV risk – REDUCE-IT Legacy
Professor C. Packard (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Long term efficacy and adherence of inclisiran in real-world clinical practice: insights from the CHOLINET Registry
Doctor F. Marzano (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Determinants of short term Lp(a) variability in phase 3 obicetrapib trials
Doctor J. Kastelein (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
HRS-7249, a small interfering RNA targeting apolipoprotein C3, in healthy subjects
Professor B. Jiang (Hangzhou, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Novel lipid‑lowering therapies for residual risk

The Event

Event poster

ESC Congress 2026

28 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
PCSK9 inhibitors: effectiveness of treatment and changes in background lipid-lowering therapy in a real world Italian population. The AT-TARGET-IT study
26 August 2022
thumbnail
Congress Presentation
Statin adherence in coronary outpatients: a novel direct method compared with pharmacy registry data
26 April 2024
thumbnail
Congress Presentation
Inclisiran patient experiences survey
13 June 2025
thumbnail
Congress Presentation
Adherence to statin therapy after inclisiran start, insights from the the DAMAGE registry
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources